[go: up one dir, main page]

FI20090384L - Menetelmä modifioidun G-CSF-polypeptidin valmistamiseksi - Google Patents

Menetelmä modifioidun G-CSF-polypeptidin valmistamiseksi Download PDF

Info

Publication number
FI20090384L
FI20090384L FI20090384A FI20090384A FI20090384L FI 20090384 L FI20090384 L FI 20090384L FI 20090384 A FI20090384 A FI 20090384A FI 20090384 A FI20090384 A FI 20090384A FI 20090384 L FI20090384 L FI 20090384L
Authority
FI
Finland
Prior art keywords
preparing
modified
csf polypeptide
csf
polypeptide
Prior art date
Application number
FI20090384A
Other languages
English (en)
Swedish (sv)
Other versions
FI123078B (fi
Inventor
Timothy D Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20090384(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI20090384L publication Critical patent/FI20090384L/fi
Application granted granted Critical
Publication of FI123078B publication Critical patent/FI123078B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
FI20090384A 1993-01-28 2009-10-21 Menetelmä modifioidun G-CSF-polypeptidin valmistamiseksi FI123078B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs
US1009993 1993-01-28
PCT/US1994/000913 WO1994017185A1 (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
US9400913 1994-01-25

Publications (2)

Publication Number Publication Date
FI20090384L true FI20090384L (fi) 2009-10-21
FI123078B FI123078B (fi) 2012-10-31

Family

ID=21743861

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953593A FI120769B (fi) 1993-01-28 1995-07-27 G-CSF-analogikoostumuksia ja menetelmiä
FI20090384A FI123078B (fi) 1993-01-28 2009-10-21 Menetelmä modifioidun G-CSF-polypeptidin valmistamiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI953593A FI120769B (fi) 1993-01-28 1995-07-27 G-CSF-analogikoostumuksia ja menetelmiä

Country Status (21)

Country Link
US (6) US5581476A (fi)
EP (8) EP2345724B1 (fi)
JP (7) JPH08506018A (fi)
KR (2) KR100375274B1 (fi)
CN (3) CN1495197B (fi)
AT (2) ATE553199T1 (fi)
AU (2) AU697451B2 (fi)
CA (4) CA2711007C (fi)
DE (1) DE69425516T2 (fi)
DK (3) DK2345724T3 (fi)
ES (3) ES2150951T3 (fi)
FI (2) FI120769B (fi)
GR (1) GR3034745T3 (fi)
IL (6) IL145994A (fi)
LU (1) LU92265I2 (fi)
LV (1) LV12642B (fi)
NO (3) NO952974L (fi)
NZ (5) NZ513422A (fi)
PT (3) PT1482046E (fi)
WO (1) WO1994017185A1 (fi)
ZA (1) ZA94568B (fi)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
EP0876401B1 (en) * 1996-01-22 2007-06-13 Curis, Inc. Methods for producing op-1 morphogen analogs
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
BR9910568A (pt) * 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1141300A1 (en) * 1999-01-06 2001-10-10 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) * 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
JP3866043B2 (ja) * 1999-04-06 2007-01-10 ザ ユーエービー リサーチ ファウンデイション 溶液結晶成長における結晶化条件をスクリーニングする方法
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
CA2372526A1 (en) * 1999-05-10 2000-11-16 Michael D. Wyrsta Methods and compositions for controlled polypeptide synthesis
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
CZ20022727A3 (cs) * 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
ES2214240T3 (es) * 2000-06-16 2004-09-16 Vsi Holding A/S Recipiente con costados plegables.
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
AU2001286931A1 (en) * 2000-08-30 2002-03-13 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
US20040254351A1 (en) * 2000-09-07 2004-12-16 Beals John Michael Hyperglycosylated polypeptides
AU2001290960B2 (en) * 2000-09-08 2007-11-01 Massachusetts Institute Of Technology G-CSF analog compositions and methods
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
WO2002073373A2 (en) * 2001-03-12 2002-09-19 Board Of Regents, University Of Texas System Ensemble-based strategy for the design of protein pharmaceuticals
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2003100002A2 (en) * 2002-05-23 2003-12-04 Board Of Regents, The University Of Texas System Predicting the significance of single nucleotide polymorphisms (snps) using ensemble-based structural energetics
AU2003256469A1 (en) * 2002-07-10 2004-01-23 Uab Research Foundation Method for distinguishing between biomolecule and non-biomolecule crystals
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
PL216545B1 (pl) * 2002-09-11 2014-04-30 Fresenius Kabi Gmbh Sposób wytwarzania pochodnej hydroksyalkiloskrobi, pochodna hydroksyalkiloskrobi, kompozycja farmaceutyczna
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
US7538092B2 (en) * 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
PT1667708E (pt) * 2002-12-26 2012-09-14 Mountain View Pharmaceuticals Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
AU2003303636B2 (en) * 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
DK2441465T3 (da) * 2003-10-24 2014-04-14 Nora Therapeutics Inc Præparater og fremgangsmåder til en sund graviditet
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
EP2286791B1 (en) 2003-12-30 2014-03-26 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
EP1758608A2 (en) * 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyethyl starch and erythropoietin
KR101186821B1 (ko) 2004-03-11 2012-09-28 프레제니우스 카비 도이치란트 게엠베하 환원성 아미노화에 의해 제조된, 하이드록시알킬 녹말 및단백질의 접합체
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US7741096B2 (en) * 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
US7790174B2 (en) 2004-12-23 2010-09-07 Merck Serono Sa G-CSF polypeptides and uses thereof
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
KR100657749B1 (ko) * 2005-04-13 2006-12-20 씨제이 주식회사 인간 과립구 콜로니 형성인자 동종체 및 그 조성물
DE602006020562D1 (de) * 2005-06-01 2011-04-21 Maxygen Inc Hren dafür
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
AU2006281638B2 (en) * 2005-08-15 2012-05-03 Phares Pharmaceutical Research N.V. Crystal forms of astaxanthin
US8017315B2 (en) * 2005-08-22 2011-09-13 Dana Farber Cancer Institute, Inc. Mitochondrial localization of MUC1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
US8129345B2 (en) * 2006-07-20 2012-03-06 Dana-Farber Cancer Institute, Inc. MUC1-IκB kinase complexes and their activities
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
JP4375412B2 (ja) * 2007-02-19 2009-12-02 株式会社デンソー 蒸発器ユニット
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CA2964910C (en) 2007-04-27 2018-01-09 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101815944A (zh) 2007-07-03 2010-08-25 安姆根有限公司 利用包含体干重的蛋白测量
ES3022264T3 (en) 2007-07-09 2025-05-28 Hoffmann La Roche Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2248832B1 (en) 2008-02-18 2014-09-03 Jiangsu Hengrui Medicine Co., Ltd. A g-csf conjugate modified by water-soluble polymer
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2323688B1 (en) 2008-07-22 2018-10-17 MenoGeniX, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
DK2352508T3 (da) 2008-10-17 2014-04-28 Dana Farber Cancer Inst Inc Muc-1 cytoplasmisk domæne-peptider som inhibitorer af cancer
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
PL3248610T3 (pl) 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
EP2548017A2 (en) 2010-03-15 2013-01-23 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
EP2550366B1 (en) 2010-03-23 2014-11-12 IMBA-Institut für Molekulare Biotechnologie GmbH Methods for identifying inhibitors of the type iii secretion system
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
PE20152005A1 (es) 2013-03-15 2016-01-29 Bayer Healthcare Llc Dominios gla como agentes terapeuticos
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
KR20180017104A (ko) * 2015-06-11 2018-02-20 앰비오 파마슈티컬스, 엘엘씨 Peg화된 과립세포 콜로니 자극 인자(gcsf)
US10947287B2 (en) * 2015-10-19 2021-03-16 Sandoz Ag DNA coding sequence for human G-CSF
WO2019051002A1 (en) 2017-09-05 2019-03-14 GLAdiator Biosciences, Inc. PROCESS FOR INTRACELLULAR DELIVERY
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
KR20220106966A (ko) * 2019-10-08 2022-08-01 자임워크스 인코포레이티드 과립구 집락-자극 인자 수용체(g-csfr)의 변형된 세포외 도메인 및 이에 결합하는 사이토카인
CA3159912A1 (en) 2019-12-17 2021-06-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel g-csf mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
AU7675487A (en) * 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
NO176799C (no) * 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68918331T2 (de) * 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0546124T4 (da) 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
AU666866B2 (en) * 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) * 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
US5866114A (en) * 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ATE251669T1 (de) 1992-11-24 2003-10-15 Searle & Co Mutierte polypeptide des interleukin-3(il-3)
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CN1124348C (zh) 1995-10-05 2003-10-15 G·D·瑟尔公司 多功能性造血受体激动剂
CA2234042A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
WO1997012978A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. NOVEL c-mpl RECEPTOR AGONISTS
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
RO120919B1 (ro) 1996-10-25 2006-09-29 G.D. Searle & Co. Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
JP2001527396A (ja) 1997-04-11 2001-12-25 ジー．ディー．サール アンド カンパニー ｆｌｔ３リガンドキメラタンパク質
EP1115854A1 (en) 1998-09-25 2001-07-18 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
JP5232352B2 (ja) 2001-10-10 2013-07-10 ノボ ノルデイスク エイ エス ペプチドの改造および複合糖質化

Also Published As

Publication number Publication date
IL145994A (en) 2010-12-30
IL108446A (en) 2003-01-12
CA2239360A1 (en) 1994-08-04
EP0890640A3 (en) 1999-03-24
PT1482046E (pt) 2012-06-06
CN1970571A (zh) 2007-05-30
ATE553199T1 (de) 2012-04-15
EP0974655A2 (en) 2000-01-26
EP0612846B1 (en) 2000-08-16
US7381804B2 (en) 2008-06-03
JP2009057368A (ja) 2009-03-19
AU8197098A (en) 1998-10-15
EP0974655A3 (en) 2001-10-24
EP1482045A3 (en) 2004-12-29
HK1107356A1 (en) 2008-04-03
DK1482046T3 (da) 2012-06-25
US20010016191A1 (en) 2001-08-23
EP1482046B1 (en) 2012-04-11
FI120769B (fi) 2010-02-26
ATE195552T1 (de) 2000-09-15
CN1495197A (zh) 2004-05-12
ES2422269T3 (es) 2013-09-10
US5790421A (en) 1998-08-04
US20030171559A1 (en) 2003-09-11
KR100375274B1 (ko) 2003-06-11
EP0612846A1 (en) 1994-08-31
JP2010059170A (ja) 2010-03-18
CN1495197B (zh) 2013-01-16
WO1994017185A1 (en) 1994-08-04
NO952974L (no) 1995-09-28
EP2345724B1 (en) 2013-07-03
CN1970571B (zh) 2013-07-10
KR100390338B1 (ko) 2003-07-07
CA2239360C (en) 2002-07-16
LV12642A (lv) 2001-04-20
IL124111A (en) 2002-09-12
NO20093489L (no) 1995-09-28
AU6095794A (en) 1994-08-15
EP1482046A3 (en) 2005-01-05
NZ332188A (en) 2000-07-28
CN1118572C (zh) 2003-08-20
AU697451B2 (en) 1998-10-08
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
DE69425516T2 (de) 2001-06-13
FI953593A0 (fi) 1995-07-27
JP2006137762A (ja) 2006-06-01
FI953593L (fi) 1995-07-27
DK2345724T3 (da) 2013-09-30
NO20031497L (no) 2003-04-02
EP1482046A2 (en) 2004-12-01
CA2381489C (en) 2010-10-19
EP0890640A2 (en) 1999-01-13
IL124112A (en) 2006-12-10
IL125398A0 (en) 1999-03-12
IL108446A0 (en) 1994-04-12
ES2382927T3 (es) 2012-06-14
CA2711007C (en) 2012-10-02
EP0965638A3 (en) 2000-02-23
NZ504840A (en) 2001-11-30
EP1482045A2 (en) 2004-12-01
HK1009288A1 (en) 1999-05-28
US5581476A (en) 1996-12-03
IL145994A0 (en) 2002-07-25
GR3034745T3 (en) 2001-02-28
JPH08506018A (ja) 1996-07-02
US6632426B2 (en) 2003-10-14
US8058398B2 (en) 2011-11-15
CA2381489A1 (en) 1994-08-04
DE69425516D1 (de) 2000-09-21
ZA94568B (en) 1994-09-12
US6261550B1 (en) 2001-07-17
ES2150951T3 (es) 2000-12-16
CA2711007A1 (en) 1994-08-04
JP2004113243A (ja) 2004-04-15
DK0612846T3 (da) 2000-10-09
JP2011207885A (ja) 2011-10-20
NO952974D0 (no) 1995-07-27
NO20031497D0 (no) 2003-04-02
EP1233065A1 (en) 2002-08-21
JP2006096762A (ja) 2006-04-13
CA2153896C (en) 1999-01-12
FI123078B (fi) 2012-10-31
US20050260154A1 (en) 2005-11-24
CN1132527A (zh) 1996-10-02
PT2345724E (pt) 2013-08-22
CA2153896A1 (en) 1994-08-04
NZ314960A (en) 1999-01-28
KR960700341A (ko) 1996-01-19
EP2345724A1 (en) 2011-07-20
NZ261765A (en) 1997-10-24
PT612846E (pt) 2001-01-31
LU92265I2 (fr) 2013-10-14
EP0965638A2 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
FI20090384L (fi) Menetelmä modifioidun G-CSF-polypeptidin valmistamiseksi
FI962069L (fi) Menetelmä karpolaktaamin valmistamiseksi
FI933357A7 (fi) Menetelmä benzamidien valmistamiseksi
FI922938A0 (fi) Menetelmä kanavanvaihdon tehostamiseksi
FI961071L (fi) Menetelmä zeoliitin valmistamiseksi
FI891480A7 (fi) Menetelmä valolla kovetettavien päällysten valmistamiseksi
FI891711L (fi) Menetelmä diorganodialkoksisilaanien valmistamiseksi
FI925988A7 (fi) Menetelmä B-laktaamien valmistamiseksi
FI933677A7 (fi) Menetelmä komposiittisorbenttien valmistamiseksi
FI924051A7 (fi) Menetelmä keskitisleiden valmistamiseksi
FI943703L (fi) Menetelmä gamma-butyrolaktonin valmistamiseksi
FI942907A7 (fi) Menetelmä lipaasin valmistamiseksi
FI955800L (fi) Menetelmä aminoalkyyliganidiinien valmistamiseksi
FI921621L (fi) Sprutmetod foer braensle
FI920861A7 (fi) Menetelmä antitrombiinisten polypeptidien valmistamiseksi
FI19992039A7 (fi) Menetelmä atsepinonien valmistamiseksi
FI931850L (fi) Menetelmä välituotteen valmistamiseksi
FI20001776L (fi) Menetelmä farmaseuttisen koostumuksen valmistamiseksi
FI942102L (fi) Menetelmä alumiinioksaanien valmistamiseksi
FI960429L (fi) Menetelmä 1,4-butaanidiolin valmistamiseksi
FI891362A7 (fi) Menetelmä uusien alkanofenonien valmistamiseksi
FI895800A7 (fi) Menetelmä uusien a-syano-b-oksopropioniamidien valmistamiseksi
FI962046A7 (fi) Menetelmä gamma-butyrolaktonin valmistamiseksi
FI932126A7 (fi) Menetelmä 2-kloori-5-kloorimetyylipyridiinin valmistamiseksi
DK44593D0 (da) Fremgangsmaade til fremstilling af et polypeptid

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 123078

Country of ref document: FI

Kind code of ref document: B

MA Patent expired